Table 3. Expected number of events, costs, and cost per additional outcome avoided (Toxoscreen project).

Assessment period	Prenatal screening (a)	Neonatal screening (b)	Difference (b–a)
Short term assessment (1 year)	Outcomes per 1000 women/children
Strictly toxoplasmosis-related events (STRE)
Live-born children with toxoplasmosis (1)	0.332	0.660	0.328
Toxoplasmosis-related fetal losses and neonatal deaths (2)	0.002	0.007	0.005
Total STRE (= 1+2)	0.334	0.667	0.333
Global events (GE)
Total GE (= STRE+ neonatal deaths, fetal losses unrelated to toxoplasmosis + abortion and fetal losses due to amniocentesis)	156.033	161.272	5.239
Mean cost per woman/child (€)	851	773	-78
Cost per additional outcome avoided
STRE			232 631.4
GE			14 826.0
Long term assessment (15 years)	Outcomes per 1000 women/children
15 years–STRE
Sequelae	0.031	0.067	0.036
Total STRE (sequelae+(2))	0.033	0.075	0.042
15 years–GE (15 years STRE + neonatal deaths, fetal losses unrelated to toxoplasmosis + abortion and fetal losses due to amniocentesis)	155.240	158.748	3.508
Mean cost (€)	826	751	-75
Cost per additional outcome avoided
STRE			1 795 145
GE			21 472

(a) Reference strategy